$AVAI

Cell therapy market expected to grow four-fold to $20 billion by 2030 as biotech companies announce major clinical advances in anti-aging and neurodegenerative treatments.

Avaí Bio and Austrianova complete GMP Master Cell Bank for α-Klotho anti-aging therapy, beginning FDA-required viral testing before manufacturing.

$AVAI and Austrianova present latest α-Klotho therapy data at Second Annual Klotho Conference in September, highlighting Cell-in-a-Box® technology for longevity protein production.

Regenerative medicine market projected at $578B faces manufacturing bottleneck as Avaí Bio advances Master Cell Bank solution enabling scalable, off-the-shelf cell therapy production.

Global cell therapy manufacturing market projected to reach $14B by 2035, with FDA regulatory flexibility accelerating approvals and multiple biotech companies advancing scalable production capabilities.

Avaí Bio achieves critical Master Cell Bank milestone for α-Klotho protein therapy, partnering with Austrianova as cell therapy market surges toward $45B by 2035.

Avaí Bio begins manufacturing genetically modified cells overexpressing α-Klotho protein, an anti-aging compound that naturally declines 50% after age 40, advancing its Cell-in-a-Box platform.